0001209191-21-043537.txt : 20210628 0001209191-21-043537.hdr.sgml : 20210628 20210628182304 ACCESSION NUMBER: 0001209191-21-043537 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210624 FILED AS OF DATE: 20210628 DATE AS OF CHANGE: 20210628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ferra Joseph J Jr CENTRAL INDEX KEY: 0001733790 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40523 FILM NUMBER: 211054996 MAIL ADDRESS: STREET 1: C/O SYROS PHARMACEUTICALS, INC. STREET 2: 620 MEMORIAL DRIVE, SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Elevation Oncology, Inc. CENTRAL INDEX KEY: 0001783032 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 841771427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 888 SEVENTH AVE STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10106 BUSINESS PHONE: 212-651-6380 MAIL ADDRESS: STREET 1: 888 SEVENTH AVE STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10106 FORMER COMPANY: FORMER CONFORMED NAME: 14ner Oncology, Inc. DATE OF NAME CHANGE: 20190719 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-24 0 0001783032 Elevation Oncology, Inc. ELEV 0001733790 Ferra Joseph J Jr C/O ELEVATION ONCOLOGY, INC. 888 SEVENTH AVENUE, 12TH FLOOR NEW YORK NY 10106 0 1 0 0 Chief Financial Officer Stock Option (Right to Buy) 16.00 2021-06-24 4 A 0 249104 0.00 A 2031-06-23 Common Stock 249104 249104 D Restricted Stock Unit (RSU) 2021-06-24 4 A 0 200995 0.00 A Common Stock 200995 200995 D 25% of the total shares will vest on June 16, 2022, and the remainder will vest as to 1/48 of the total award in monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. 25% of the RSUs will vest on June 16, 2022, and the remainder will vest in quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. /s/ Shawn Leland, Attorney-in-Fact 2021-06-28